Unicycive Therapeutics (UNCY): Vivo Opportunity reports 9.99% beneficial ownership stake
Unicycive Therapeutics, Inc. disclosed in an amended Schedule 13G that Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity, LLC report beneficial ownership of 4,856,259 shares, or 9.99%, based on 27,855,257 shares outstanding as of Aug. 12, 2026. The stake includes 550,000 common shares plus conversion of Series A-3/A-4/A-5 preferred underlying warrants exercisable within 60 days.
How this was made
The 30-second read
Why it matters
The key tradable element is governance and control risk from a holder at 9.99% with sole voting and dispositive power, plus conversion-linked exposure within 60 days.
Market read
This is a regulatory ownership update that can matter for control dynamics, but it does not include new corporate actions, clinical, or financing terms.
What to watch
The 9.99% conversion cap via blocking provisions could limit actual voting dilution dynamics, reducing immediate control impact versus the headline percentage.
Background
The text summarizes an amended SEC Schedule 13G reporting beneficial ownership by Vivo Opportunity entities in Unicycive Therapeutics.
Ticker impact
Unicycive Therapeutics discloses Vivo Opportunity’s amended Schedule 13G showing 9.99% beneficial ownership, including conversion-linked preferred warrants.
Near-term price reaction is likely limited unless follow-on activism, board changes, or financing terms are disclosed; watch for further 13D/13G amendments.
The article is a regulatory ownership disclosure (Schedule 13G) with detailed share and conversion mechanics, but it does not state new activism, deal terms, or operational catalysts.
Market effects
For small-cap biotech, large near-threshold ownership stakes can signal potential governance pressure, but this filing alone does not change sector fundamentals.
None indicated.
None indicated.
Counterpoint
The stake may be passive and already contemplated; without a shift to Schedule 13D or explicit activism, the market may discount the signal.
Key entities
- issuerUnicycive Therapeutics, Inc.
Subject of the Schedule 13G ownership disclosure, with shares outstanding and conversion-linked warrant mechanics described.
- investorVivo Opportunity Fund Holdings, L.P.
Reporting person holding beneficial ownership of 4,856,259 shares, including common and conversion-eligible preferred warrant tranches.
- general partnerVivo Opportunity, LLC
General partner listed as part of the reporting structure for the beneficial ownership position.
